Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz,  Who Bring Deep, Relevant Experience in Life Sciences

GlobeNewsWire • Aug 3, 2026

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company's primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company's clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer's disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.

GlobeNewsWire • Jul 30, 2026

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026.

GlobeNewsWire • May 22, 2026

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company's former Senior Vice President of Clinical Development and current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of President and Chief Executive Officer Christopher Missling, PhD, MS, MBA, from the Company on April 30, 2026, and a request for his resignation from the Board of Directors.

GlobeNewsWire • May 6, 2026

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine

GlobeNewsWire • Apr 14, 2026

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026.

GlobeNewsWire • Apr 7, 2026

Anavex Life Sciences Provides Comprehensive Regulatory Update

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease

GlobeNewsWire • Mar 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Mar 27, 2026

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.

Benzinga • Mar 25, 2026

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA). The decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time.

GlobeNewsWire • Mar 25, 2026